APA (7th ed.) Citation

Marmé, F., Werft, W., Keller, S., Wang, X., Benner, A., Burwinkel, B., . . . Schneeweiss, A. (2012). CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer. Breast cancer research and treatment, 132(3), . https://doi.org/10.1007/s10549-011-1759-9

Chicago Style (17th ed.) Citation

Marmé, Frederik, et al. "CD24 Ala57Val Polymorphism Predicts Pathologic Complete Response to Sequential Anthracycline- and Taxane-based Neoadjuvant Chemotherapy for Primary Breast Cancer." Breast Cancer Research and Treatment 132, no. 3 (2012). https://doi.org/10.1007/s10549-011-1759-9.

MLA (9th ed.) Citation

Marmé, Frederik, et al. "CD24 Ala57Val Polymorphism Predicts Pathologic Complete Response to Sequential Anthracycline- and Taxane-based Neoadjuvant Chemotherapy for Primary Breast Cancer." Breast Cancer Research and Treatment, vol. 132, no. 3, 2012, https://doi.org/10.1007/s10549-011-1759-9.